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ABSTRACT: Early diagnosis and efficient treatment are of paramount importance to fight 
cancers. Monitoring the foreign body response of a patient to treatment therapies also plays an 
important role in improving the care that cancer patients receive by their medical practitioners. 
As such, there is extensive research being conducted into ultrasensitive point-of-care detection 
systems and “smart” personalized anti-cancer drug delivery systems. Electrospun nanofibers 
have emerged as promising materials for the construction of nanoscale biosensors and 
therapeutic platforms due to their large surface areas, controllable surface conformation, good 
surface modification, complex pore structure, and high biocompatibility. Electrospun 
nanofibers are produced by electrospinning, which is a very powerful and economically viable 
method of synthesizing versatile and scalable assemblies from a wide array of raw materials. 
This review describes the theory of electrospinning, achievements, and problems currently 
faced in producing effective biosensors/drug delivery systems, in particular, for cancer 
diagnosis and treatment. Finally, insights into future prospects are discussed. 
KEYWORDS: Electrospinning, nanofibers, drug delivery, biosensing, cancer
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21. INTRODUCTION
Mortality statistics by geographical location reflects a concerning consistency in cancer. It 
accounts for a large proportion of recorded deaths in many areas of the world, with 9 million 
deaths by cancer being approximated worldwide in 2016,1 accounting for 15.8% of the overall 
57 million reported deaths. Some technological advancements in the past decades have 
provided the necessary framework to address some of the medical issues associated with 
specialized therapy procedures. In almost all cancers, the average 5-year survival rate has 
improved by up to 2.3% in 2016 alone.2 Nevertheless, mortality rates for neoplastic related 
deaths have declined in a comparatively stagnant fashion relative to circulatory diseases over 
the past three decades (Figure 1). Currently, employed methods of treatment include a 
combination of surgery, chemotherapy, radiation therapy, immunotherapy, and target-specific 
therapies.3 A fundamental shortcoming of these treatments is that they are often implemented 
as part of a mitigating methodology when cancer diagnostics have identified malignant tumors.
The need to pursue more effective means of cancer treatment becomes clear when 
currently employed methods are considered. Synergistic radiotherapy / surgical resection and 
systemic chemotherapy – the commonly applied therapeutic strategy4 – are limited in their 
application due to adverse health effects that accompany their administration. In the absence 
of selectivity for neoplastic cells, common health side effects that are observed might include 
kidney malfunction, nerve injury, nausea and vomiting,5 normal cell toxicity, and death due to 
extreme dosages.6 This is a direct result of the traditional drug delivery process, i.e., repeated 
administration of treatment via the oral or parenteral route7. Naturally, with each dosage cycle, 
the drug concentration in the blood quickly rises and then declines.6 As every drug has a plasma 
concentration above which it is toxic and below which it is useless,8 this method of 
administration is susceptible to accidental or intentional overdose, substance abuse, or simple 
ineffectiveness.7 As such, nanoscale therapeutics have currently been the focus of much 
Page 2 of 80
ACS Paragon Plus Environment
ACS Biomaterials Science & Engineering
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
3experimental effort due to their ‘biomimetic’ approximation of the extracellular matrix 
(ECM)’s topography, allowing specific unloading of therapeutic cargo at the tumor site without 
systemic administration.6,7 At the expense of lower loading capacity, the nanometer scale 
allows drug-delivery across the cell membrane, which simultaneously minimizes drug uptake 
by the reticuloendothelial system and unwanted clearance from the body through the spleen or 
liver,9 the net effect of which is an improved therapeutic index relative to traditional drug 
delivery.
Figure 1. Age-standardized mortality rates by cause of death from 1982-2013. Produced by the 
authors using published U.K. government statistics.2
In recent years, the ability to design novel approaches for cancer treatment has been 
facilitated by a greater understanding of the tumor microenvironment.10 For example, as 
neoplastic cells overexpress certain proteins and characteristic biomarkers, we could design 
platforms to target them. The advent of nanoscale technology has provided great opportunities 
in therapeutic treatment, with the potential to create “smart”, personalized anti-cancer 
therapies, and a new generation of biosensors11 designed to detect a specific biological 
analyte.12 For instance, nanomaterials derived from inorganic and carbonaceous materials have 
been developed for fabricating, e.g. volatile organic compound sensors for cancer diagnostic 
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4purposes.13 However, poor thermal stability and selectivity to the desired biological analyte 
have imposed several practical limitations in employing them for routine clinical application.14 
Nanoparticles and hydrogels have been identified as potentially valuable platforms for in vivo 
cancer therapy as they allow for targeted and/or local delivery of therapeutic agents. However, 
their efficacy is constrained by short circulation times in the case of nanoparticles, and by 
significant wash-out of encapsulated drugs during the gelation period in the case of hydrogels.15 
Among the numerous nanomaterials, recently, electrospun nanofibers (ESNFs) have 
attracted much interest as a construction material for drug delivery platforms/biosensors due to 
their large surface area, controllable surface conformation, good surface modification, complex 
pore structure, and high biocompatibility.11,16–19 Due to their high drug loading efficiency and 
increased surface-to-volume area, ESNFs are in many ways superior to other small drug 
carriers as they allow for the administration and delivery of substances via a range of different 
routes. ESNFs can be dispensed in the body through common (oral, buccal, sublingual , rectal, 
vaginal, etc.)20–22 and topical (transdermal, ocular, inhalation)23 routes or in the form of local 
or loco-regional implants. ESNFs also allow topical controlled drug release, that makes them 
optimal for cancer therapy.15 Furthermore, electrospun nanofibers can be biodegradable, unlike 
silicone-based ones. Electrospun nanofibers have better in vitro and in vivo sensitivity than 
other sensors due to their small size and the enhancement of the mass transport limiting 
membrane.24 Furthermore, biomimetic coatings that can be achieved by electrospinning, which 
can prevent biofouling, thus increase the lifetime of biosensors.24 ESNFs are produced by the 
process of electrospinning, which permits a simple, variable, and effective synthetic route to 
prepare and control the production of nanofibers. Moreover, ESNFs have been fabricated and 
hybridized with functional additives to diversify their application to many fields. This review 
seeks to investigate the novel approaches in designing biosensors based on electrospun 
nano/microfibers and study their applications from the development of ultrasensitive sensors 
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5to drug delivery systems. Additionally, the pharmacokinetics of antineoplastic agents 
incorporated with nanofibers in mediating tumor area-specific release will be examined. 
Contributions from various research groups in this field will give a clear indication of the 
origins, current status, and potential development of ESNF-based biosensors for use in cancer 
diagnostics. 
2. FABRICATION OF NANOFIBERS BY ELECTROSPINNING
2.1 Electrospinning process 
Electrospinning is a highly versatile method to process solutions, suspensions or melts, 
into continuous fibers with nano/microscale diameters.25 It is the only method for mass-
producing continuous long nanofibers.26 The process uses a high voltage that charges the liquid 
inside a metallic capillary. A standard laboratory-scale setup consists of four main components: 
a high voltage power supply, a syringe pump, a nozzle (usually metallic), and a collector (which 
can simply be metallic foil/plate/disk).27 The electrostatic force produced by the high voltage 
supply is applied to a polymer solution or melt, which is dispensed through the fine needle 
orifice at a controlled rate. Accumulated charge at the spinneret orifice subjects the discharged 
polymer melt to an electric field, which induces a conically-shaped geometry to form (termed 
the ‘Taylor cone,’ Figure 2.B).11,27 Increasing the strength of the electric field increases the 
accumulated charge on the surface of the budding polymer droplet, generating repulsive 
electric forces that overcome the surface tension of the polymer solution/melt.18 The resulting 
jet that is dispensed from the tip of the Taylor cone experiences electrical instabilities by the 
applied electric field, which causes it to elongate through the application of a mechanical force 
(Figure 2.A). The drawn polymer thread is directed to the oppositely charged or grounded 
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6collector, and the residual solvent evaporates leaving only the charged polymer fiber on the 
collector mat (Figure 2.C).19 
Figure 2. Needle Electrospinning. (A) Schematic diagram of an electrospinning needle 
system using a single needle in a vertical configuration.28 (B) Forces acting on the tip of 
spinneret during the formation of a Taylor cone. (C) Horizontal configuration needle 
electrospinning.28 Setups represented with a static collector plate, but other configurations 
exist. Panels A and C reproduced with permission from ref 28. Copyright 2017 Elsevier. 
Panel B adapted with permission from ref 29. Copyright 2009 IIT Delhi.
2.2 Electrospinning parameters and their influence on fiber morphology
The collected fibers have a nano/microscale diameter with improved modular strength.11,27  
They also resemble the ECM, making them ideal candidates for biological use. In order to use 
the produced electrospun fibers for biosensing, their morphological properties often need to be 
tweaked to produce patterned nanostructures with the objective of optimizing performance 
parameters of bioreceptors (e.g., response time, stability, and sensitivity).11,27 This is often 
achieved by using additives during or after the electrospinning process, which are immobilized 
inside or on the surface of the nanofibers.30 The recognition element is interfaced to an 
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7immobilized bioreceptor and signal transducer (e.g., an electrochemical, optical, mass, or 
calorimetric- based transducer) which amplifies bioassay signal outputs for data processing.31 
After detection, novel approaches to introducing additives in the form of chemotherapeutic 
agents favor local drug delivery systems (DDS), where antineoplastic drugs are encapsulated 
or loaded on biodegradable nanofiber (NF) scaffolds.19 The immobilization of the additives 
(e.g., bioreceptors and/or antineoplastic agents) is dependent on the physical and chemical 
properties of the NF-interstitial matrix, and the interactions between them.11 Each component 
of the biosensor contributes heavily to its functionality and effectiveness; as such, careful 
modification of electrospinning parameters - which generates an array of morphologies - 
addresses this highly selective behavior. Table 1 summarizes the parameters that influence 
fiber morphology. 
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8Table 1. Parameters of electrospinning and their influence on fiber morphologies.11,19
Parameter  Influence
Solution Parameter Viscosity Fiber diameter increases and the bead formation decreases with 
increased viscosity
 
Molecular Mass Influences viscosity (vide supra); higher molecular mass results 
in a more uniform morphology
 Concentration Increases viscosity and amount of deposited nanofibers
 Conductivity Fiber diameter decreases with increasing conductivity; ionic 
materials can reduce atomization of polymer jet
Solvent Properties Surface Tension Bead formation may occur if surface tension is considerable 
(relative to the viscosity)
 Vapor Pressure Influences solvent evaporation during spinning; solvent 
evaporation may influence the formation of non-cylindrical 
morphologies
Operating 
Conditions
Applied Voltage Decreasing fiber diameter with increasing voltage supply
 Solution Flow Rate Lower flow rates = smaller diameter fibers
Higher flow rates = larger diameter fibers and/or non-dry fiber 
deposition at the collector surface
 Distance of collector 
from nozzle
Fiber solidification; deposition area, increases with increased 
distance between collector and nozzle  
 Collector Type Aligned fibers, yarns, braided, or random fibers can be obtained 
by changing from a plate to a drum, area, etc. type collector
 Tip Hollow or blended fibers may be obtained; increasing tip 
diameter increases the final fiber diameter
Surrounding 
Conditions
Temperature Influences the fiber diameter through temperature-viscosity 
relationship indirectly (decrease in viscosity with an increase in 
temperature), and directly increases the product yield/fiber 
diameter by changing the evaporation rate of the solvent 
 Humidity High humidity may result in circular pore formation in fibers, 
which can lower the solvent evaporation rate.  Low humidity 
may produce thicker fibers, due to rapid solvent evaporation. 
Further, high humidity can affect the total charge distribution 
on the Taylor cone, reducing the surface charge density and 
thus affecting the electrospinnability of the polymer solution.
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92.3. Properties of electrospun nanofibers with different morphologies
Of interest to biosensor applications (aside from the standard smooth surface, solid interior 
NF) are the porous,32–34 nanoparticle-decorated,35,36 core-shell,28,37 and hollow7,38,39 
nanostructures (Figure 3). 
Figure 3. Fiber Morphologies: (A) Biomimetic multichannel microtubes. (B) Hollow nanofibers. (C) 
Nanoparticle-decorated nanofibers. (D) Core-shell nanofibers. (E) Porous nanofibers (red arrows 
depict pore structures). (F) Single electrospun nanofibers. Panel A reproduced with permission from 
ref 40. Copyright 2007 American Chemical Society. Panel B reproduced with permission from ref 41. 
Copyright 2010 American Chemical Society.  Panels C and E reproduced with permission from ref 
36. Copyright 2018 Radacsi, N.; Campos, F. D.; Chisholm, C. R. I.; Giapis, K. P. Panel D reproduced 
with permission from ref 42. Copyright 2012 Elsevier. Panel F reproduced with permission from ref 
43. Copyright 2019 American Chemical Society. 
These specially fabricated morphologies have higher surface areas than the solid interior NFs, 
with a greater number of immobilization sites to interface receptors to and improve the 
performance of ESNF biosensors; Table 2 compares the relative merits and shortcomings of 
each morphology.
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10
Table 2. Comparisons of the advantages and disadvantages of core-shell, porous, and hollow 
electrospun morphologies.16
Co-axial electrospinning is performed by fitting a small capillary inside a larger outer 
capillary. The inner capillary contains the core polymer, while the outer capillary produces the 
shell polymer.37 The polymer solutions are discharged while being subjected to an applied 
electrical field, conceptually similar to the single-solution electrospinning technique.27 The 
interactions that govern the resultant core-shell NF properties are derived from the degree of 
rheological, physical, and chemical dissimilarity between the two polymer solutions;28 
however, a uniformly incorporated core-shell fiber is expected to form if a stable Taylor cone 
is maintained.44 Processing parameters related to coaxial electrospinning are reviewed in 
numerous literature sources,41,45 all of which agree that the complexity of coaxial 
electrospinning originates from the difficulty in maintaining a stable Taylor cone. To induce a 
stable Taylor cone, process parameters should be such that: (1) An electrospinnable shell 
solution is utilized; (2) the shell solution viscosity is higher than the core solution viscosity (so 
that viscous stresses between the core and shell solutions overcome the interfacial tension 
between them)46; (3) a low vapor pressure solvent is used (fast evaporation may destabilize the 
Morphology Advantages Disadvantages
Core-Shell - Large surface area
- Unique properties
- Selectable Core & Shell 
materials
- Complex synthetic route
- Harsh post-treatments (which may 
denature biological components)
Porous - Simple to synthesize
- Versatile application
- Equipment-independent
- Complex pretreatment required
- Uncontrollable loading of nanoscale 
building blocks
Hollow - Large surface area - Specific equipment required
- Complex synthetic route
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Taylor cone); and (4) a greater shell solution conductivity is used (to inhibit core-shell 
structural discontinuities induced by rapid core polymer elongation).28
Hollow NFs may be produced using the co-axial electrospinning technique. Co-axial 
production of nanotubes was first introduced by Loscertales et al.47 and Li & Xia48 in 2004, 
presenting a single-step synthesis of hollow NFs by coaxially electrospinning two immiscible 
liquids. A shell-forming sol constituent is gelated prior to being electrospun with an inert, 
immiscible core liquid, after which charge induced mechanical forces break up the nanojet, 
forming hollow NFs with liquid-filled cores. Evaporation of the liquid-filled core during NF 
elongation leaves only hollow NFs. Loscertales et al.47  postulated that in order to maintain the 
hollow fiber morphology, the shell material should be able to withstand the capillary forces 
generated after core removal. Similarly, Li & Xia48 stated that the presence of a ceramic sol-
gel precursor in the shell material was a necessary requirement in order to form stable coaxial 
jets with robust tubular structures. In this, the fabrication process for hollow morphologies is 
more stringent compared to porous morphologies (similar to that of the core-shell 
morphology); however, the resultant surface area is greater,49 corresponding to a greater 
loading capacity for immobilizing transducing elements.
Porous nanostructures can be obtained by blending removable inorganic nanoscale 
building blocks into polymeric matrices and post-treating with organic solvents, removing the 
nanoscale building blocks to produce porous NFs.27 Additionally, polymeric porogens may be 
utilized as sacrificial polymer templates, whereby differences in physical properties between 
the electrospun NF-polymeric porogen matrix (synthesized using simple electrospinning 
techniques) is exploited in post-treatment processes to remove the porogen component.16
Nanoparticle-decorated nanofibers can be prepared in one step (during the electrospinning 
process) or in multiple steps (deposition of nanoparticles after the electrospinning). The 
addition of nanoparticles on the surface of electrospun nanofibers can provide secondary or 
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12
tertiary functions that serve to improve upon the performance of non-functionalized 
nanofibers,35,36
3. ELECTROSPUN FIBERS IN BIOMEDICAL APPLICATIONS
The structure produced by the electrospinning setup provides a spatiotemporal 
configuration with the ability to sequester stimulants in various compartments, similar to in 
vivo conditions.28 This means that it is possible to modulate the release kinetics of various 
antineoplastic agents by manipulating the fiber thickness and localization. The release of 
cytotoxic treatment is unfortunately limited by the pore architecture of NF matrices through 
which it is dispersed. An NF mesh with a too small diameter-to-porosity ratio will impede the 
incorporation of interstitial additives into the scaffold material.28 This characteristic is desirable 
in barrier applications for the skin and endothelium, but not efficient for cancer treatment and 
detection.50 Integrins (more specifically αvβ3, a class of animal transmembrane proteins 
involved in cell-cell adhesion and substrate engagement) are known to play an important role 
in cytoskeletal organization of the cellular membrane.51 Integrin expression is upregulated on 
angiogenic endothelial cells; if αvβ3 is blocked with selective antibodies or (Arginine-Glycine-
Aspartic acid)-containing peptides, angiogenic endothelial cells in vivo will possibly disrupt 
metastatic mechanisms and undergo apoptosis.52,53 Aside from the chemical signaling initiative 
provided by the interstitial additive, the topological features of ESNFs predominate in the 
foreign body response of patients, suggesting mechanisms that potentially hinder or accelerate 
the migration and binding of target-moieties to biosensors.51 Therefore, ESNFs assembled to 
approximate an ECM architecture can, to a degree, control the activity of integrins; otherwise, 
there may be counteracting integrin-dependent proliferation signals.52 Brigger et al.54 
developed this idea in their research into nanoparticle DDSs (of the nanosphere, polymeric 
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matrix variety). They reiterated the potential DDS capabilities of nanoscale polymer matrices, 
postulating the strategy of in vivo treatment using drug-loaded colloidal systems. Non-modified 
nanoparticles were rapidly opsonized by macrophages in the mononuclear phagocytes system 
(MPS) (Liver, lungs, spleen, bone marrow), resulting in higher concentrations of administered 
therapeutic agents in the spleen, liver, and lungs of mice. The propensity for MPS macrophages 
to undergo endocytosis/phagocytosis restricted the use of non-surface-modified nanoparticles 
to MPS-specific tumors. Surface characteristics of the traditional nanoparticle matrix were 
modified with hydrophilic-moiety, and the surface curvature has increased above 100 nm, 
reducing opsonization by MPS macrophages and prolonging the DDS’ half-life. This allowed 
selective extravasation of cytotoxic agents through the leaky vasculature surrounding 
neoplastic cells, extending its application to tumor sites outside the MPS system. This stresses 
the importance of spatial architecture on effective DDSs and applies equally to any foreign 
substance that is administered into the body of a patient. 
For a similar reason, a considerable challenge in the production of nanoscale biosensing 
devices is maintaining bioreceptor functionality.11 For example, incorporation of antibodies as 
an interstitial additive requires a chemically favorable environment in the NF matrix. 
Antibodies can conjugate randomly to nanofibrous surfaces through carbodiimide-mediated 
conjugation routes, which may reduce the activity of the antibody.55,56 A study conducted by 
Liang et al.57 in 2005 on in vitro non-viral gene delivery with nanofibrous scaffolds examined 
the parameters affecting successful transfection. Polylactide-co-glycolide (PLGA) ESNF 
scaffolds were loaded with DNA particles. Two preparation methods were conducted: (1) DNA 
was condensed in a solvent mixture, followed by encapsulation in a triblock copolymer of 
poly(lactide)-b-poly(ethylene glycol)-b-poly(lactide) to form micelles. The micellar mixture 
was electrospun with PLGA to form a nonwoven nanocomposite and nanofibrous scaffold 
(with a core-shell structure) using coaxial electrospinning techniques. (2) DNA was simply 
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14
incorporated with the PLGA and electrospun thusly. The authors57  observed that DNA which 
was not encapsulated in the copolymer was degraded because of the electrospinning process, 
displaying no transfection. In comparison, the DNA encapsulated in the copolymer was 
virtually undisturbed, attributable to the core-shell structure protecting the DNA, allowing 
transfection to take place. The juxtaposition of the two results highlights the difficulty in 
maintaining bioactivity of interstitial additives. If biological agents are to be incorporated into 
electrospun structures, then special consideration of the biological function in which they are 
to be implemented must be upheld. This is of little consequence to the delivery of non-
biological therapeutic agents such as heparin (an anticoagulant), which has been successfully 
incorporated in ESNF mats with uniform distributions in previous studies.58,59 A polymer melt 
was prepared by loading heparin in a 7:3 v/v dichloromethane: methanol solution, which was 
used to dissolve the polymer.58 The collected fibers (produced using a flow rate of 0.5 mL h-1 
of polymer melt and a 0.8 kV cm-1 applied electric field between the capillary and the collection 
plate) were sterilized in 70% ethanol baths for 15 minutes followed by 5-minute cycle washes 
in cell culture media.  Sustained diffusional release of biologically functional heparin was 
obtained over a 14-day period, highlighting its validity as a DDS for local administration to the 
site of vascular grafts. Evidently, the end objective of the electrospinning process demands 
careful consideration of the factors affecting it, be it biosensing, drug delivery, or otherwise.
4. ELECTROSPUN NANOFIBERS FOR BIOSENSORS
4.1. The Bioreceptor
The bioreceptor plays the role of molecular recognition, producing a physiochemical 
response to interactions with a biological analyte (i.e., biocatalysis, immunological coupling, 
chemoreception, etc.)31 to be detected by a signal-transducing element. The compact analytical 
device is represented generally in Figure 4. It has been noted in many studies that the functional 
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significance of biomarkers for early cancer detection is insurmountable. It is not the objective 
of this literature review to provide an account of biomarkers that have been identified as cancer-
indicating. Instead, a partial list of the most promising analytes and their conjugate bioreceptors 
are provided in Table 3 to aid the reader in the subsequent discussion.
Figure 4. Principle of function of a biosensor. A biological analyte in a complex media 
specifically interacts with an immobilized bioconjugate on the biosensor surface. The output 
signal is converted into a physical readout signal via a transducer. Incompatible analytes will 
not interact to produce a signal output. Reproduced with permission from ref 60. Copyright 
2002 Springer-Verlag. 
It is interesting to note that despite the exceptionally greater scholarly effort into NF 
systems for cancer therapeutics (compared to in vitro diagnostics), comparatively few have 
been approved for clinical trial. A study conducted in 2006 reported over 150 companies 
developing nanoscale therapeutics, with only 23 being approved for clinical use, 3 for in vivo 
imaging, and 2 for in vitro diagnostics; collectively the market value was estimated at $6.2 
billion (£14.86 billion, adjusting for inflation).61 In 2008, the US Federal Drug Administration 
and European Medicines Agency approved only a few for cancer treatment.55 As of 2016, 51 
FDA-approved nanomedicines were identified, and a further 77 products were in clinical trial 
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stages.62 The FDA-approved nanotherapeutics were predominantly polymeric, liposomal, or 
nanocrystal formulations; more complex materials comprising micelles or protein-based 
nanoparticles are yet to be FDA-approved. While ESNFs for cancer treatment are mostly in 
their infantile or preclinical stages, it is worth observing that the detection and treatment of 
cancer are synergistic, so for optimal results both the local detection and delivery of cytotoxic 
treatment should be employed clinically. Biosensors are utilized more liberally due to their 
diverse portfolio, including glucose monitoring for diabetes,63 food quality and safety,64 
fermentation processes,65 and environmental pollution control.66 Exploiting biosensors for 
disease screening and diagnostics is not a new concept; however, its employment in 
conjunction with DDSs appears novel. Not including the technological difficulties in 
constructing DDSs and ultrasensitive biosensors, it is evident that legal, ethical, and economic 
restrictions constrain its widespread adoption as primary point-of-care treatment presently.
Table 3. Promising analytes and their conjugate bioreceptors for cancer diagnostics and 
treatment.
Recognition 
Element
Analyte Bioreceptor Anatomical Relevance in 
Cancer Detection
Source
Antigen/Antibody PSA anti-PSA Prostate 56,67
CA 125 anti-CA 125 Ovarian, Uterus, Pancreas, 
Liver, Colon
12 
CEA anti-CEA Breast, Colon 12 28 
Enzyme Glucose GOx n/a 63,68
ITIH4 Peptide-specific 
antibody
Ovarian, Breast, Colon, 
Prostate
69 
HRP H2O2 Breast 11
Receptor HER-2 / EGFR 
family
anti-HER-2 Breast, Colon, Lungs 55,70
Folate Folic acid-liposomal 
conjugates
Ovarian, Lung, Brain, Head 
& Neck, Renal
55 
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PSA = Prostate Specific Antigen; CA 125 = Cancer Antigen 125; CEA = Carcinoembryonic 
antigen; ITIH4 = Inter-alpha-Trypsin Inhibiter Heavy chain family member 4; HRP = Horse 
Radish Peroxidase; HER-2 = Human Epidermal growth factor Receptor 2.
4.2. Bioreceptor Immobilization 
Part of the construction of biosensors requires immobilization of the bioreceptor onto 
ESNF matrices by conjugation; this process is selective. This means that an immobilization 
method optimized for a particular bioreceptor does not apply uniformly to all bioreceptors. Just 
as conjugation of biological analytes to bioreceptors is selective (Table 3), the technique must 
be adjusted to conform to the unique properties of a given bioreceptor. The typical conjugation 
routes for tumor targeting is provided in Table 4.
Recent advances in bioconjugation techniques have been widely reviewed in the 
literature;73–75 however, a brief outline of the most common techniques prevalent to cancer 
optimized biosensors will be provided. Immobilization is classified under reversible processes 
(Adsorption and Bioaffinity) and irreversible processes (Covalent Binding, Cross-Linking, and 
Entrapment),74 represented in Figure 5. Adsorption (physical), bioaffinity, and entrapment are 
physical methods of immobilization while covalent bonding, adsorption (ionic), and cross-
linking are chemical methods.
Table 4. Bioconjugate Components and designs for tumor targeting application.75
Bioconjugate 
Components
Bioconjugate Reagents Bioconjugate Designs
Nucleic Acids p53 n/a Lung, Neck, Brain, 
Leukemia, Colon, Breast
71,72,11
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Polymers; dendrimers; 
cytotoxic agents; 
toxins; enzymes; 
prodrugs; haptens or 
ligands; antibody or 
antibody fragments  
Heterobifunctional aliphatic 
crosslinkers; heterobifunctional PEG-
based crosslinkers; PEGylation agents; 
multifunctional scaffolds; zero-length 
crosslinkers; homobifunctional 
crosslinkers; thiolation reagents; 
spacer arms
Antibody-drug; 
antibody-enzyme; 
antibody– polymer–
drugs; antibody–
polymer–dye–drug; 
hapten–drug; ligand-
drug
Figure 5. Bioreceptor Immobilization Methods. (A) Adsorption, physical and ionic binding. 
(B) Bioaffinity-based immobilization. (I) Covalent binding through primary amines. (II) 
Entrapment on beads or fibers and micro-encapsulation. (III) Cross-linking using 
carbodiimide mediated conjugation. Reproduced with permission from ref 73. Copyright 
2016 Susana Liébana, Guido A. Drago. 
4.2.1. Reversible Processes
Adsorption (by physical or ionic binding) represents the easiest method of immobilization, 
where the ESNF matrix is enriched with bioreceptor molecules at the vicinity of the interface. 
Physical adsorption (Figure 5 (A)) of the bioreceptor molecules occurs by weak intermolecular 
interactions (i.e., hydrogen bonding, van der Waals forces or hydrophobic interactions) 
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between the adsorbate (the bioreceptor) and the adsorbent (the ESNF surface). Ionic 
chemisorption simply binds the biological agent through salt linkages. 
Bioaffinity immobilization (Figure 5 (B)) occurs via two alternative routes. In the first, 
the bioreceptor species is conjugated to a ‘fusion tag’ molecule which has an affinity for the 
ESNF matrix. In the second, the ESNF matrix is activated and precoupled with an affinity 
ligand, after which the bioreceptor is added. The precoupling process can be conducted by any 
covalent bonding mechanism used for generating affinity media; however, if the affinity ligand 
is a biologically active protein, then the precoupling process should optimize the number of 
accessible binding sites between the target analyte and bioreceptor, which ultimately 
determines the sensitivity and stability of the biosensor. Even so, the unique characteristics of 
this method pose some challenges to its eventual commercialization due to affinity ligands 
being, on occasion, economically infeasible, unstable in vivo, or difficult to isolate.76
4.2.2. Irreversible Processes 
Covalent binding (Figure 5 (I)) immobilizes the bioreceptor onto the ESNF matrix by 
covalent bonding. This process is widely used when designing biosensors due to the stability 
of the bond, which precludes the leaching of bioreceptor molecules into the surrounding 
solution, thereby allowing prolonged in vivo measurements to be taken.77 Active binding sites, 
such as the antibody recognition areas should not be blocked by this process, as this counteracts 
the objective of biosensing. Generally, five functional groups have been identified as the 
necessary precursors to covalent binding immobilization in practical conjugation methods. 
These are: Primary amines (-NH2) (can be targeted without denaturing the bioreceptor using 
N-hydroxysuccinimidyl ester reactive groups); Carboxy groups (-COOH) (usually available on 
the bioreceptor surface as a C-terminus in polypeptide chains); Thiols    (-SH) (disulfide bonds 
between cysteine groups in the bioreceptor can be reduced to thiols using maleimide -or 
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iodoacetyl-activated reagents for thiol-directed conjugation); Carbonyls (-CHO) (can be 
created by glycosylation of glycoproteins with sodium meta-periodate); Carbohydrates 
(oxidized sugars can be reacted to hydrazide-activated groups or primary amines through 
reductive amination).73 
Entrapment is the method of choice for the immobilization of enzymes with low molecular 
weight substrates in polymeric networks. The occlusion of bioreceptors in the ESNF matrix 
occurs by physically caging the enzyme (not binding it, see Figure 5(II)), allowing substrates 
and products to selectively permeate through the caged structure while still maintaining 
bioactivity.78 Access to binding sites on the enzyme can be inhibited by the ESNF enclosure, 
preventing the use of bioreceptors with high molecular weight substrates.
Cross-linking immobilization chemically joins the bioreceptor to the ESNF matrix by an 
intermediary cross-linker molecule which contains two (or more) reactive functional groups 
(Figure 5(III)). Many cross-linker molecule variants are available for immobilizing specific 
bioreceptors (Table 4). For instance, bioconjugates made with HRP for developing western 
blots can be immobilized using zero-length cross-linkers, where the carbohydrate on the 
glycoprotein is oxidized and subsequently coupled to a target molecule by reductive 
amination.75 
4.3. The Biosensor 
The immobilization and stabilization of the bioreceptor occur principally on the 
transducing element of the ESNF biosensor complex. Occasionally, immobilization may take 
place on functional additives that are incorporated to improve the analytical performance of the 
biosensor.73 Transducing elements are categorized into electrochemical, calorimetric-based, 
optical, or mass-based.12 Currently, the distribution of reported biosensors favors the use of 
electrochemical biosensors, with 89% being documented as electrochemical, 9% as optical, 
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and 2% as mass or calorimetric.56 An earlier analysis in this literature review on the biological 
detection behavior of biosensors has emphasized the importance of bioreceptor functionality. 
In truth, effective transduction of analyte response signals is heavily dependent on the 
dispersion behavior and biological compatibility of functional additives in ESNFs; likewise, 
physical characteristics of the transducing elements contribute significantly to the overall 
performance of the biosensor.16 The following discussion will focus mainly on providing an 
account of ESNF electrochemical biosensors, their synthetic routes, and their application in 
cancer detection. A brief discussion will follow on the use of optical, mass, and calorimetric 
biosensors, and their application in cancer detection.
4.3.1. Electrochemical Biosensors
Electrochemical biosensors (ECBSs) are currently the most mature biosensing devices 
used in practice.12 Characteristics of this variant of biosensor, derived from microelectronic 
circuits, include robustness, easy scalability, portability, excellent detection limits (even with 
a small analyte volume), and the ability to be employed domestically as point-of-care devices.12 
Principally, the ECBS operates by extracting electrical response signals from biological 
analytes that react electrochemically with the surface of a working electrode. The response 
signal is either a measurable current (amperometric; linear concentration dependence), a 
measurable potential (potentiometric; logarithmic concentration dependence), or a measurable 
alteration in the conductive properties of a medium between two electrodes (conductometric).79 
The recognition element is typically an enzyme due to its high catalytic activity and selective 
binding between the analyte and bioreceptor.80 However, immunosensors - in which antibodies 
are coupled to electrochemical transducers - have also been widely employed in the 
measurement of cancer biomarkers, especially prostate-specific antigens.81
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Electrodes in the ESNF matrix serve as the transducing element of the biosensor, usually 
requiring a minimum of three to be used in electro-active responses. A reference electrode, 
commonly made of silver, is isolated from the surface reaction and maintained at a fixed 
potential from which measurements can be compared. The working electrode (cathodic or 
anodic mode) transduces the measured electrochemical response, while the auxiliary electrode 
connects the working electrode to an electrolyte solution, inducing a current for operation.82 
The properties of the electrode material influence the response time, stability, and sensitivity 
of the biosensor, but transducer-immobilized enzymes often exhibit inefficient electron transfer 
for signal transduction.83 This is the result of unfavorable enzyme orientation to the electrode 
surface, which inhibits a rapid exchange of electrons. The sensitivities of unaltered ECBSs are 
rarely useful for biomarker detection as a result. By modifying the transducer with highly 
conductive and chemically stable additives such as carbon nanotubes (CNTs), metal 
nanoparticles, and quantum dots (QDs),84 it is possible to improve an ECBS’s sensitivity and 
signal-to-noise ratio79 through facilitated electron transport between the bioreceptor and 
electrode.77 Furthermore, studies have demonstrated a strong adsorption capacity for enzymes 
on these nanoscale building blocks, subsequently improving the response time, sensitivity, and 
stability (by minimizing enzyme unfolding) of ECBSs.85 The homogeneous distribution of 
these nanoscale building blocks is vital to ensure good performance, so dispersion strategies 
for nanoscale building blocks in ESNF-ECBSs will be discussed. 
4.3.1.1. Pre-Processing Modification of Nanoscale Building Blocks in Electrospun 
Nanofibers
The pre-processing method of ESNFs introduces nanoscale building blocks by adding the 
desired modifier to the polymer melt before being electrospun into nanofibrous scaffolds.86 
Theoretically, the greater the nanoscale building block content in the polymer melt, the more 
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even the distribution through the ESNF matrix, and the greater the performance of the ECBS. 
These properties are mutually inhibited, however, as nanoscale building blocks have higher 
surface energy than the ESNF matrix often leading to aggregation.16 Pre-processing methods 
of overcoming this aggregatory behavior include blending of nanoscale building blocks 
(through external force-assisted dispersion or anisotropic additive-promoted dispersion) or in 
situ synthesis of nanoscale building blocks in ESNFs.  
4.3.1.1.1. Blending of Nanoscale Building Blocks in Electrospun Nanofibers
Dispersion of nanoscale building blocks in ESNFs can be assisted by external driving 
forces - such as ultrasonic treatment or adding surface-active agents16  - or adding anisotropic 
materials to ESNF matrices, which promotes a more uniform distribution in the polymer melt 
after being electrospun.36 Generally, it is a metal nanoparticles that are loaded in the polymer 
melt for ECBSs due to their good dispersion, and optimal conductive properties,86 however, 
organic nanostructures may also be utilized in, for example, near-infrared imaging for early 
cancer detection87 or as fluorescence probes for bioimaging.88–90 Diamond nanostructures have 
emerged as attractive materials in biomedical applications such as bioimaging, biosensing, and 
drug delivery due to their exceptional mechanical, thermal, optical, and electrical properties.91 
Additionally, it has been noted in previous studies that Ag, Au, Pt, Cu, and Ni nanoparticles 
have very good electrochemical activity towards H2O2, the analyte conjugated to HRP that is 
prevalent in breast cancer monitoring (see Table 3). The works of Devadoss et al.92 present 
their findings on synthesizing (Au nanoparticle)-composite Nafion NFs (specifically: (Au 
nanoparticle)-Nafion-polyacrylic acid (PAA) NFs) using the simple electrospinning technique 
outlined in section 2. N,N’(4-dimethylamino) pyridine (DMAP) and DMAP-protected (Au 
nanoparticle)-incorporated Nafion NFs were directly mixed and electrospun on a stainless steel 
working electrode, after which HRP was immobilized on the electrode surface by physical 
Page 23 of 80
ACS Paragon Plus Environment
ACS Biomaterials Science & Engineering
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
24
adsorption in the presence of poly(acrylic acid) molecules. Electron microscope imagery 
compared the (Au nanoparticle)-composite with the (Au nanoparticle)-free composite, 
revealing a high surface area and uniform distribution of Au nanoparticles in the composite 
NFs. This homogenous inclusion was attributed to the strong electrostatic interactions between 
the negatively charged sulfonate groups in Nafion and the positively charged DMAP-protected 
Au nanoparticles. It was demonstrated that the (Au nanoparticle)-composite electrodes, when 
employed as reservoirs for horseradish peroxidase immobilization, produced reliable and 
sensitive electrochemical detection of the enzymatic reaction occurring on the surface. The 
sensitivity was improved by order of magnitude compared to previous ECBSs (with a limit of 
detection = 38 nM), and the bioreceptor remained biologically stable for over three weeks. 
A recent review on metal-oxide NF-based ECBSs38 provides an account of current 
advancements in the production of ESNFs doped with metal-oxide precursors. These metal-
oxide NFs are produced by blending an inorganic precursor with a polymer solution and 
electrospinning using co-axial,28,37 colloid-,93 solution- (see section 2),94 and melt-
electrospinning95 techniques. While melt-electrospinning eliminates the need for harsh organic 
solvents, the necessary elevated operating temperatures (between 60°C and 90°C)50 may 
preclude its use in biosensor application by potentially denaturing immobilized enzymes. 
Nevertheless, a metal-oxide derived ESNF mat can be synthesized by evaporating a sacrificial 
polymer carrier and oxidizing an inorganic precursor, promoting fiber-aligned, uniform 
nucleation of metal-oxide nanoscale building blocks in a polymer matrix.38 The resultant 
morphological properties include a high surface area-to-pore ratio and diverse pore 
architecture, which increases the number of available bioreceptor binding sites and further 
improves the biosensor sensitivity. Indeed, mesoporous zinc oxide (ZnO) ESNF-ECBSs with 
high sensitivity, reproducibility, and stability were successfully fabricated and reported by Ali 
et al.96 for the detection of anti-epidermal growth factor receptor 2 (overexpressed in breast 
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cancer patients). High sensitivity (7.76 kΩ µM-1), low detection limit (1 fM), fast detection 
time (128 s), and a broad detection range (1 fM - 0.5 µM) was obtained, corresponding to an 
order of magnitude improvement in sensitivity relative to the then-current best in literature,97 
and three orders of magnitude improvement relative to the Enzyme-Linked ImmunoSorbent 
Assay standard for breast cancer biomarker detection. Similarly, ZnO ESNFs doped with 
multiwall carbon nanotubes (MWCNTs) have been produced by blending a three-component 
mixture (of ZnO, MWCNTs, and polymer melt) and electrospinning for use in CA 125 analyte 
detection (see Table 3).98 Highly oriented ZnO nanowires were embedded in the ESNF matrix 
by a one-step calcination process at a temperature that simultaneously avoided MWCNT 
decomposition and created MWCNT-ZnO functional groups for antibody immobilization, 
resulting in an immunosensor with good dispersion of MWCNTs and high electrocatalytic 
activity. A particularly promising development in the field follows the recently published 
works of Tripathy et al.99. The authors present their findings on synthesizing an electrospun 
semi-conducting Manganese (III) Oxide (Mn2O3) NF ECBS for DNA hybridization detection. 
The Mn2O3 NFs were synthesized by blending a polyacrylonitrile / N,N-dimethylformamide 
polymer matrix with a known weight % of Manganese (II) Acetate tetrahydrate and stirring for 
1 hour at 60°C and then 2 hours at 65 °C. The precursor solution was electrospun to form a 
free-standing nonwoven NF membrane; collected NFs were then calcinated at 500 °C to obtain 
homogeneously dispersed Mn2O3 NFs. The DNA probe was immobilized by covalently 
binding the amine groups on the nucleotide to activated carboxylic groups on the Mn2O3 NF 
matrix, shown in Figure 6. 
Page 25 of 80
ACS Paragon Plus Environment
ACS Biomaterials Science & Engineering
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
26
Figure 6. Schematic representation of a proposed DNA-hybridization semi-conducting 
Manganese (III) Oxide electrochemical biosensor. GCE = Glassy Carbon Electrode, MNF = 
Modified nanofiber, MPA = Mercaptopropionic acid, EDC = 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide, NHS = N-hydroxysuccinimide. Reproduced with 
permission from ref 99. Copyright 2017 Elsevier. 
It was demonstrated that the Mn2O3-doped ECBS performed better than the unmodified ESNF-
ECBS, obtaining unprecedented sensitivities (up to 6.93 kΩ mol-1cm-2) and a zeptomolar limit 
of detection (120 x 10-21 M). The authors attribute these properties to a decreased charge 
transfer resistance in the system, promoted by accumulation of negatively charged ssDNA 
probes on the semiconducting NF coating. Additionally, the accumulated charge produced a 
Mn2O3 NF matrix with a lower band structure than conventionally wide bandgap material 
approaches, significantly enhancing the limit of detection of biological analytes in ECBSs. This 
synthetic methodology is especially attractive for biosensors used in cancer detection as the 
immobilization and functionalization protocols are generic in nature. The ECBS could be 
extended to any of the recognition elements outlined in Table 3 simply by modifying the 
Page 26 of 80
ACS Paragon Plus Environment
ACS Biomaterials Science & Engineering
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
27
working electrode with probe sequences specific to the desired biological analyte, providing 
an almost all-inclusive anatomically relevant platform for point-of-care lab-on-chip cancer 
diagnostics. 
4.3.1.1.2. In Situ synthesis of Nanoscale Building Blocks in Electrospun Nanofibers
In situ synthesis requires dispersing metallic ions in a polymer solution before 
electrospinning, thereafter reducing the uniformly distributed ions to metallic nanoscale 
building blocks by heat-, light-, additives, or electro-stimulation.100 Several medically relevant 
ESNFs have been functionalized with nanoscale building blocks using in situ methods, 
including: GNP-doped polyacrylonitrile ECBSs by an oxidation-reduction reaction,101 hybrid 
silica-PVA NFs by sol-gel electrospinning,32 CNT- and Pt nanoparticle-doped polyvinylidene 
difluoride NF membranes for biosensor application,102 and Ag-doped ZnO nanoparticles on 
electrospun cellulose NF mats by hydrolysis.103 As the nanoscale building block precursors are 
added in their ionic form, the aggregatory behavior characteristic of pre-processing blending is 
avoided. In this, in situ synthesis is the preferable approach for metal nanoparticles; however, 
this strategy is exclusive to metallic based nanoscale building blocks and cannot be employed 
for doping ESNFs with CNTs, MWCNTs, or other non-metallic nanoscale building blocks. 
Interestingly, there are many instances in literature where metal-oxides have been introduced 
to ESNFs in situ as a surface coating.33,39,73,104–106 After electrospinning a polymer-precursor 
solution, calcination of the organometallic metal-oxide / sol-gel precursor caused the NF 
diameter to contract. This induced a brittle fiber morphology, onset by internal mechanical and 
thermal stresses.104 Generally, supplementary materials which are both mechanically and 
chemically stable during the calcination process are embedded in polymer-precursor solutions 
before being electrospun to preserve the ESNF’s structural integrity. The principle that only 
surface-bound nanoscale building blocks interact with recognition elements - meaning 
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internally dispersed nanoscale building blocks contribute little to the transduction of biological 
response signals107 - suggests that in situ surface coated metal-oxide ESNFs are promising 
materials for biosensor applications. On the nanoscale, however, morphological processing and 
surface arrangements of nanoscale building blocks are of paramount importance in improving 
the sensitivity of biosensors to cancerous analytes, an issue which is best addressed by synthetic 
post-processing routes.
4.3.1.2. Post-Processing Modification of Nanoscale Building Blocks in Electrospun 
Nanofibers
The post-processing method of synthesizing ESNFs with nanoscale building blocks 
requires decorating an as-spun NF matrix with functional additives by various immobilization 
techniques. 
4.3.1.2.1. Core-Shell Morphology 
Regardless of complex post-treatments restricting its broader application, core-shell NFs 
have been adopted previously as ESNF-ECBSs for cancer detection. Li et al.108 reported their 
findings on synthesizing an immunosensor for CEA-biomarker detection. A nanoporous 
gold/chitosan modified paper working electrode was used as the sensor platform, and graphene 
QD functionalized bimetallic Platinum-coated gold (Au@Pt) core-shell nanoparticles were the 
signal labels.108 Anti-CEA antibodies were subsequently immobilized by covalent assembly of 
signal antibodies on graphene QD tagged Au@Pt core-shell nanoparticles, following a 
sandwich-type immunoreaction in which graphene QDs / Au@Pt labels were captured onto the 
NGC-PWE surface.108 The proposed strategy produced an immunosensor with a detection 
range of 1.0 pg mL-1 - 10 ng mL-1, and a limit of detection of 0.6 pg mL-1, comparable in 
performance to the best commercial graphene / CNT based ECBSs.108 The authors also 
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remarked that the synthetic technique they employ can be readily expanded to detecting other 
cancer biomarkers and that its potential for ultrasensitive cancer diagnostics is very 
promising.108
Core-shell ESNFs have also been fabricated and reported by Li et al.109 and Shen et al.110 
as novel H2O2 ECBSs. Li et al. constructed a piece of conductive cloth from electrospun 
polycaprolactone (PCL) NFs decorated with polypyrrole (PPy)-coated silver nanoparticles 
(Ag@PPy), which formed the core-shell structure of Ag@PPy / PCL@PPy. The flexible 
conducting cloth was successfully pasted onto a glassy carbon electrode for biosensory 
application, showing good electrochemical activity toward the direct reduction of H2O2 with a 
limit of detection down to 1 µM and a broad linear detection range of 0.01 mM - 3.5 mM. 
Likewise, Shen et al. described the synthesis of a novel core-shell hybrid H2O2 biosensor, 
utilizing both in situ and synthetic post-processing routes. SiO2@Au NFs were produced by 
electrospinning a silica sol precursor, after which gold seed particles were grown in situ via a 
layer-by-layer self-assembly method. Gold shells were then used to encapsulate the SiO2@Au 
NFs, forming the gold-coated silica fiber hybrid material. The nanocomposite displayed 
excellent chemical stability, biocompatibility (with horseradish peroxidase, see Table 3), as 
well as a high sensitivity (from 5 µM to 1 mM with a limit of detection of 2 µM), indicative of 
an ECBS platform with a high level of variability. 
4.3.1.2.2. Porous Morphology 
Cui et al.111 constructed a carbon NF-hydroxyapatite (HA) composite by assembling HA 
onto carboxylic group-functionalized carbon NFs and post-treating with acid and thermal 
processes. SEM images of the CNFs-HA composite displayed a homogenous and porous 
structure, providing a large electrode surface area for the loading of metalloprotein Cytochrome 
c (Cyt c) in H2O2 biodetection.111 The CNFs-HA composite ECBS obtained better performance 
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than previously documented Cyt c loaded biosensors, displaying good analytical performance 
(linear detection range from 2 µM - 8.7 µM, limit of detection of 0.3 µM) facilitated by a Cyt 
c loading capacity that was double that of traditional CNT loading capacities.111  
Mondal et al.38 recently reported a facile method for fabricating functional micro-, 
submicro-, and nano-channels embedded in porous carbon film ECBSs. The microfluidic 
platform was constructed by electrospinning a skin layer of poly(methyl methacrylate) solution 
on a silicon wafer substrate, followed by a spin coating of polyacrylonitrile. Thermally-induced 
carbonization of the composite film decomposed the poly(methyl methacrylate) NFs, 
producing embedded microchannels in the polyacrylonitrile-derived amorphous monolithic 
carbon electrode. Pt nanoparticles were then in situ assembled on the embedded channels by 
thermal decomposition of a precursor salt to enhance the performance of the carbon electrode.38 
Further plasma treatment functionalized the composite surface with carboxylic groups, 
allowing anti-aflatoxinB1 (anti-AFB1) antibodies to be grafted by carbodiimide-mediated 
conjugation routes.38 An improved ECBS performance was obtained, attributable to aligned 
nanochannels in the porous carbon film which simultaneously acted as a reaction chamber for 
antigen-antibody interactions and a fast electron transport route between the electrolyte and 
working electrode. The synthesized immunosensor had a higher detection range than 
previously reported AFB1 sensors and a comparable picomolar limit of detection. Even though 
the proposed immunosensor was produced for the detection of AFB1 (prevalent in the food-
processing industry), synthesizing antigen-immobilized ESNFs with microfabricated channels 
represents a novel success in the development in state-of-the-art microfluidic devices.112–114 
Incorporation of microfluidic channels into the porous carbon film serves to improve the 
sensitivity, stability, and reproducibility of the immunosensor by maintaining the anti-AFB1 
functionality.115 This result appears analogous to the discussion of Tripathy and co-workers’ 
report (see section 4.3.1.1.1.). This synthetic route could be extended to the development of a 
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broad range of cancer-detecting biosensors by modifying the immobilization and 
functionalization protocols. According to the literature, the four areas in cancer diagnostics in 
which microfluidic-hybridized-ENSFs may change the current paradigm are: (1) Molecular-
scale diagnostics; (2) Tumor biology; (3) High-volume screening for therapeutics; and (4) 
Cancer cell isolation.114 The microfluidics field is a rapidly expanding area in cancer detection, 
and there are already instances of approved diagnostic applications.116 A particularly active 
research group in this regard is the team of Prof. Hsian-Rong, who developed multiple 
generations of “NanoVelcro” cell-affinity substrates, in which circulating tumor cell (CTC) 
capture agent-coated nanostructured substrates were utilized to immobilize CTCs with high 
efficiency.117,118 Guarino and Ambrosio provide an extensive review on the role of 
microfluidics and ESNFs in the future of cancer diagnostics.114 Integration of these 
technologies represents an innovative platform for fabricating complex nanoscale systems as 
in vitro models for toxicological investigation; however, its adoption as a primary diagnostic 
tool remains a largely unknown proposition to-date.116
4.3.1.2.3. Hollow Morphology
Ji et al.119 fabricated cationic polyelectrolyte-doped hollow NFs by coaxially 
electrospinning a core/shell solution of poly(allylamine hydrochloride) (PAH) / polyurethane 
(PU) using a specially designed two-capillary spinneret; the spinneret was designed such that 
in situ encapsulation of bioactive molecules prevents them from being contacted by the organic 
solvent. Doping of PAH on the PU ESNF allowed Candida antarctica lipase B and glucose 
oxidase enzymes to be precisely grafted in spatially isolated compartments on the ESNF 
surface and lumen by ion-exchange interactions between the charged enzymes and ionizable 
groups on PAH, producing woven-membrane NFs with enhanced enzymatic stability. The 
multienzyme ESNF system has good potential for being employed as an ultrasensitive cancer 
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biosensor, assuming transducing elements can be successfully incorporated into the 
structure.  Enzyme biomarker irregularities in certain cancers (i.e., overexpressed ITIH4 (Inter-
alpha-Trypsin Inhibitor Heavy chain family member 4) and underexpressed apolipoprotein A1 
in ovarian cancers)69 could be independently targeted using a single ESNF platform, whereby 
multienzyme cascade reactions in vivo could provide an unsurpassed efficiency/specificity for 
biosensors monitoring cancer progression. The complexity involved in constructing a 
multienzyme system that simultaneously inhibits negative interferences between grafted 
enzymes and performs multistep biotransformations might prove too complex for constructing 
a feasible biosensor. Nevertheless, if multiple enzymes could simultaneously be targeted, it 
would improve the diagnostic value of the biosensor as a single biomarker can be indicative of 
a variety of different cancers. 
4.3.2. Optical Biosensors
Optical biosensors (OBSs) use light-based sensing methods that measure changes in 
specific wavelengths of light, which are converted into an electrical readout. Most 
commercialized platforms use fluorescence labels as the detection system; however, 
interferometry and spectroscopy of optical waveguides and surface plasmons resonance are 
also available 120. The signal readout instrumentation is usually expensive relative to ECBSs, 
so their employment in cancer biosensing is relegated to predominantly laboratory-based 
testing rather than point-of-care devices for in vivo analysis 12. OBSs have been used to detect 
cancerous analytes such as CEA,121 PSA,122 volatile organic compounds,123 and histamine (for 
breast, colon, and pancreatic cancers).124
ESNF-OBSs appear to be particularly useful in detecting early-stage lung cancers. 
Considering that lung cancer has one of the greatest mortality rates of all known cancers,125 
early diagnosis is of paramount importance to avoid metastasis. Davis et al.123 demonstrated a 
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novel dual-mode optical sensing platform for volatile organic compound differentiation. 
Polydiacetylene (PDA)-embedded ESNFs were produced by mixing a diacetylene monomer 
solution with an acidic solution for 60 minutes. The resultant sol-gel was electrospun at a rate 
of 0.1 - 1.0 mL h-1, subject to an 8 - 20 kV electric field, towards a grounded aluminum plate 
(tip-to-collector distance: 10 - 12 cm). For fluorescence measurements, a poly(ethylene oxide) 
matrix polymer was used to construct PDA-embedded NFs, which were subsequently 
photopolymerized under UV irradiation to produce fluorescence responsive ESNFs. The 
solvent-dependent fluorescent transition of NFs generated a response pattern that was 
successfully used to distinguish between four different organic vapors (THF, chloroform, 
methanol, and hexane). It was further shown that the fluorescent and colorimetric sensing of 
biotin-avidin interactions could be realized by embedding biotinylated-pentacosadiynoic acid 
monomers into silica-reinforced nonwoven NF mats. There is a possibility to broaden the 
application to different cancer monitoring by generalizing the detection response to hapten 
bioconjugate interactions (see Table 4). Finally, a three-component PDA NF sensor array was 
fabricated and tested against eight different organic amine vapors. Using colorimetry and 
principal component analysis, analyte-dependent colorimetric responses were observed 
(attributable to amine specific basicity and steric hindrance). This result is particularly useful 
in lung cancer detection as two of the amine vapors tested were piperidine and pyridine, a class 
of aromatic amines. Human exhaled breath contains hundreds of volatile organic compounds, 
and aromatic amines are known biomarkers used to predict lung cancer.19 The sensor array 
differentiated between the eight amine vapors in 72 different samplings, all within a 95 % 
confidence interval.19 Ultrasensitive detection and differentiation of volatile organic 
compounds that are indicative of onset lung cancers prove to be a very promising platform for 
early lung cancer detection, suggesting the OBS proposed by Davis et al.123 could be employed 
as a novel biosensor that utilizes the technique of electrospinning. 
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Similarly, Ifegwu et al.126 fabricated nylon 6 NFs doped with Au nanoparticles for the 
colorimetric probe of 1-hydroxypyrene, a biomarker associated with the largest class of cancer-
causing compounds: polycyclic aromatic hydrocarbons. Au nanoparticles were in situ 
embedded by chemisorption between the Au nanoparticles and the amide groups on the nylon-6 
backbone.126 The nylon-6 / Au nanocomposite was electrospun to form uniformly dispersed 
nanoparticle-doped NFs.126 A prominent spectroscopic feature of Au nanoparticles is surface 
plasmons resonance, which arises from the collective oscillatory behavior of Au’s free 
electrons of the conduction band that prompts an intense absorption band in the visible 
spectrum.126 As such, the resultant ESNF was characterized by a highly sensitive, photostable 
reddish-white fiber that turned blue/purple when in contact with a standard solution of 1-
hydroxypyrene.126 Au nanoparticles have also been functionalized with DNA and grafted onto 
ESNFs for detecting nucleic acid-based marker, which are used to monitor not only lung 
cancers, but also neck, brain, colon, and breast cancers.127 Wang et al.127 introduced a facile 
approach to fabricating a novel nanocomposite membrane for highly specific and sensitive 
detection of nucleic acids. DNA-functionalized Au nanoparticles were assembled on cellulose 
acetate ESNFs to be used as a fluorescent platform which was highly sensitive, selective, and 
reproducible, as well as low-cost to fabricate.127 Further to fluorescent and colorimetric 
sampling, Au-labelled targeting molecules can be used as high-contrast agents to visualize 
injected substances in cells or tissue sections.75 Detection of such Au nanoparticle conjugates 
is particularly effective by electron microscopy, as individual particles can be precisely 
imaged.75 To that end, Au nanoparticles have been used previously as theranostic agents 
(simultaneous diagnosis and treatment) in photothermal therapy, where irradiation of Au 
nanoparticles incorporated in as-spun NFs causes them to heat up due to Au nanoparticles 
absorbing photon energy. The small size and rapid heating of Au nanoparticles, as well as the 
ability to precisely monitor their locations, provides the necessary framework for selective 
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heating and destruction of neoplastic cells without damaging the surrounding healthy tissue.10 
Photothermal treatment by shortwave radiofrequency ablation could be applied with Au 
microelectrodes to penetrate deep-seated tumors, noninvasively.128 However, its employment 
as a theranostic agent suggests that non-enzymatic bioreceptors would be required, as high-
temperature Au nanoparticle-doped ESNFs would likely denaturize any biological components 
immobilized on the surface. 
4.3.3. Mass-Based Biosensors
Mass-based biosensors (MBBSs) utilize piezoelectric techniques, where crystals produce 
readout signals based on differential mass measurements that arise from the application of a 
potential force.12 Immunosensors and microcantilever sensors that adopt piezoelectric 
technology are designed to detect cancerous analytes by immobilizing the appropriate 
conjugate on a sensor chip.120 Electrospinning has been used previously to fabricate 
piezoelectric materials for biomedical application, including polyvinylidene polymer NFs 
embedded with barium titanate nanoparticles129 and poly(vinylidene fluoride) / PAN-based 
superior hydrophobic piezoelectric solids derived by aligned MWCNTs.130 Recently, Zhao et 
al.131 demonstrated that poly(L-lactic acid) (PLLA) NFs can display piezoelectric properties 
along their diameter fiber direction, where previously documented PLLA MBBSs132 were only 
able to obtain shear-direction piezoelectricity. The authors attribute this success to the twisting 
of C=O dipoles in the polymer chains along the shear fiber direction, which was obtained by 
generating a high DC electric field and applying it to the polymer melt during 
electrospinning.131 Typically, the helical conformation structure of PLLA orients the dipole 
components perpendicular to the fiber chain direction, such that adjacent polymer chains will 
be arranged antiparallel to each other, shown in Figure 7.133 This results in a configuration that 
does not permit piezoelectricity along the fiber diameter direction. By applying shear force and 
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a strong electric field in the same direction, Zhao et al.131 were able to align the C=O dipoles 
along the polymer chain and induce piezoelectricity across the fiber diameter.131 The ESNFs 
were further functionalized with two Au electrodes after being hot-pressed for 30 minutes at 
50 MPa, from which supercritical CO2 post-treatment produced a PLLA ESNF with 61.8% 
crystallinity.131 An output current and voltage of 8 pA and 20 mV, respectively, was obtained 
by a simple push-release response to an applied force perpendicular to the fiber length.131 It is 
stated that this device enables a broad range of promising future applications in the field of 
biosensing.131 It is possible to consider adapting the push-release response to detecting surface 
stresses induced by bioreceptor-analyte specific binding. A NF mat woven using this process 
could produce a highly sensitive MBBS with a very high surface area, corresponding to a 
greater bioreceptor immobilizing capacity. Intuitively, a high concentration of grafted 
bioreceptors interacting with target analytes would result in an output response proportional to 
the number of bound target analytes, perhaps validating it as a novel biosensor platform for 
cancer detection. More experimental effort is required to corroborate this remark.
Figure 7. Poly(L-lactic acid) (PLLA) Nanofiber. (Left) Molecular geometry of PLLA. 
(Middle) Helical structure of PLLA, where shadowed circles denote carbonyl carbon atoms, 
and outer large circles denote the methyl groups. (Right) Crystal structure of the α-form of 
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PLLA with top and profile projections. Adapted for reprint with permission from ref 133. 
Copyright 2003 American Chemical Society. 
4.3.4. Calorimetric Biosensors
Calorimetric Biosensors (CBSs) measure changes in heat from enzymatic exothermic 
reactions, which can be used to measure analyte concentrations.12 There are very few instances 
in literature where CBSs are used in cancer diagnostics; fewer still, ones that utilize the 
technique of electrospinning. However, an ESNF-CBS with cancer-detecting potential was 
recently reported by Gonzalez and Frey.134 Poly(vinyl caprolactam) (PVCL) was 
copolymerized with hydroxymethyl acrylamide (NMA), after which it was electrospun and 
thermally cured to produce P(VCL-co-NMA) temperature-responsive chemical hydrogel NFs. 
The temperature response was measured using a swelling-shrinking experiment, and all 
samples responded quickly and reversibly to changes in temperature.134 This unique property 
may be utilized more in the future, presuming nanotechnology continues to mature. 
5. DRUG DELIVERY SYSTEMS USING ELECTROSPUN NANOFIBERS
Size variations within the nanoscale enable nanoparticles – functionalized, or not, with 
conjugated biomolecules for specific intracellular targeting – to be introduced into the body 
with varying bioavailability and blood circulation times.135 It has been demonstrated  that 
nanoparticles with diameters less than 10 nm are removed from the body by extravasation and 
renal clearance,136 nanoparticles with diameters greater than 200 nm are typically removed by 
phagocytes,10 and nanoparticles between 10 nm and 100 nm can penetrate small capillaries,9 
be sequestered in endocytic vesicles,137,138 and circulate for prolonged periods of time, 
suggesting optimal nanoparticle diameters fall between 10 nm and 100 nm in size.139,140 The 
delivery vehicle for parenteral administration of these nanoparticles is typically a liposomal or 
polymeric carrier.9 While liposome assisted drug delivery has been the subject of a plethora of 
Page 37 of 80
ACS Paragon Plus Environment
ACS Biomaterials Science & Engineering
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
38
positive results in preclinical trials, clinical translation has progressed moderately due to 
problems with industrial scalability, post-modification functionality, pharmacokinetic 
evaluation, and release profile moderation.141 In contrast, polymeric DDSs are capable of 
controlled and sustained release of therapeutic agents as the biochemical properties of 
encapsulation systems are optimized according to the release profile needed for a given target 
tissue.142 An ideal universal drug-delivery platform is not likely to be obtained, however 
polymeric DDSs represent a promising pre-requisite for future generation DDSs which might 
incorporate combinatorial biosensing feedback as well as in vivo release of cytotoxic treatment. 
As such, ESNF DDSs will be critically reviewed in their biomedical context.
ESNFs may be fabricated as implantable DDSs for cancer therapeutics, analogous in 
principle to the synthetic methodology employed in ESNF biosensors. Morphological 
properties of ESNFs saturated with cytotoxic agents contribute significantly to drug release 
kinetics.27 ESNFs with a high surface-area-to-volume ratio can accelerate the dissolution of 
therapeutic agents in an aqueous environment, enhancing the drug release efficiency in 
localized tumors.16,143 For this reason, most examples of ESNF-DDSs practice coaxial 
electrospinning to obtain core-shell or hollow NFs (see Table 2). Further to ESNF 
morphologies, drug release profiles have been shown to be controlled by the composition and 
concentration of shell polymers, solvents used, drug/protein concentration, surface additives, 
electrospinning conditions, and the solubility characteristics of bioactive agents.59 Therapeutic 
agents in an electrospun matrix rely on the surrounding fluid to permeate into the scaffold in 
order to dissolve it so that it can be released by either a diffusion, leaching, or combinatorial 
mechanism. The rate at which drugs are released in vivo depends on the pharmacokinetics once 
they are incorporated within NFs; to mediate tumor area-specific release, drug-polymer process 
parameters can be selected to optimize the release kinetics indirectly. ESNFs that are 
biodegradable and biocompatible have become the new tendency due to their dual-use in DDSs 
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and in implantable scaffolds.19 In contrast to non-biodegradable polymers, in which the drug-
diffusion distance is dependent on a fixed geometry, drug-diffusion in biodegradable polymers 
is a  function of the polymer degradation rate, introducing another order of complexity to the 
fabrication process.144 So far, popular biodegradable electrospinnable polymers identified in 
the literature are polycaprolactone, polyvinyl alcohol, cellulose acetate, gelatin and zein 
protein.28 Generally, natural polymers (such as cellulose acetate, gelatin, and zein protein) are 
the best choice for biocompatibility as they facilitate cell attachment / cellular activity and 
possess functional groups compatible for hydrophilic interactions; this is especially appropriate 
if the therapeutic agent is bioactive in nature. Considering most instances of sustained drug 
release are reported for small hydrophobic drugs or large biological macromolecules, chemical 
and thermal modifications can destabilize the desired physiological properties.51 In this respect, 
care must be taken to achieve designs of considerable utility. 
5.1. Modes of Delivery for Electrospun Nanofibers
A common approach employed for the delivery of ESNF drug-loaded systems is through 
the  oral,20 buccal145 and sublingual22 routes; where the drug is rapidly metabolized in the oral 
cavity.  A range of hydrophilic polymers can be appropriate for the development of such 
systems, including poly(vinyl alcohol) (PVA),20 poly(vinyl pyrrolidone) (PVP)146 and 
poly(ethylene oxide) (PEO)147.
Through the transdermal route, drugs are administered and delivered locally or 
systematically via the skin. Transdermal drug delivery is a desired alternative to oral delivery, 
which can be advantageous over hypodermal injections, as a less invasive alternative.23 This 
approach is of interest for drug-loaded systems that cannot be taken up by the oral route due to 
rapid enzymatic gastrointestinal and hepatic pre-systemic metabolism.148 Due to the nano-
dimensions and the high-surface-to-volume ratio of the ESNFs, good dispersity of the drug on 
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the polymer matrix can be achieved, significantly increasing the solubility of the drug at the 
surface of the skin.149
The ocular route is a minimally-invasive approach of targeted delivery of ESNFs through 
the ocular tissues. Aside from the direct delivery path, such an approach carries disadvantages 
due to the need of semi-transparent membranes, difficulties in application, and potential 
contaminations. Nonetheless, the usage of ESNF as a topical system for the delivery of 
substances can be beneficial in comparison to eye drops where less than 5% of the contained 
drug reaches the desired tissue.150 
In a more direct approach, anti-cancer ESNF scaffolds can be placed on the tumor bed for 
systemic localized delivery.151 Because the majority of the ESNFs follow a passive diffusion 
release behavior, thus lacking the ability of controlling the need of reaching the desired 
substance concentration for effective killing of the cancer cells, stimuli-responsive (pH-
dependent, photothermal or magnetic trigger of drug release) smart drug delivery ESNFs with 
on-demand drug release capabilities have attracted much attention.152 Chemotherapeutic in-
stent devices consisting of an ESNF surface that can be surgically placed at the tumor-bearing 
area in cancers, such as ureter153 or colorectal154 cancer, is another approach that can provide 
systemic drug release of anticancer drugs along with providing the required mechanical 
stability to prevent restenosis caused by tumor ingrowth.154 
5.2. Release Behavior of Drug-Loaded Electrospun Nanofibers
The solvent-drug and polymer-drug compatibilities are particularly noteworthy interactions 
in controlling drug release rates, so detailed strategies have been outlined in the literature144 for 
pairing solvents compatible with polymers to mitigate phase separation of drug-loaded ESNFs 
(which can result in a burst release of therapeutic agents upon dissolution). In short, to achieve 
a high drug loading efficiency, hydrophilic drugs are paired with hydrophilic ESNFs, and 
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hydrophobic drugs with hydrophobic ESNFs.59 A strategy adopted by many authors requires 
blending polymers with both hydrophobic- and hydrophilic-moieties, which further helps 
diversify the drug loading range of ESNFs.59 By utilizing the high surface areas of coaxially 
spun hollow and/or core-shell NFs with multiple therapeutic agents, one could not only 
incorporate multiple stimulants in a single therapeutic platform but also tailor the release of 
each agent independently by altering the fiber thickness and localization 28. It has been 
remarked that these morphologies also provide the additional benefit of inhibiting the initial 
burst release response.37 
For instance, Bonadies et al.155 developed new drug administration systems from 
poly(butylene adipate/poly(vinylpyrrolidone) core/shell ESNFs for malaria and prostate cancer 
applications. A considerable burst release was observed in polymer blends with a greater drug-
to-poly(vinylpyrrolidone) ratio; this is characteristic of hydrohpilic shell-polymers accelerating 
hydrophobic drug solubilization upon immersion in an aqueous environment.155 Subsequent 
diffusion from the hydrophobic core-polymer – and the low solubility of the anti-malarial drug 
– resulted in the sustained release of remaining treatment at a controlled rate.155 Polymer blends 
with a lower drug-to-poly(vinylpyrrolidone) ratio performed the best for in vitro inhibition of 
malarial parasites, and furthermore reduced the viability of prostatic cancer cell.155 
Ramachandran et al.156 developed a flexible theranostic implantable system for prolonged and 
sustained (30 days, zero-order) release of Temozolomide, an anti-glioma chemotherapeutic 
drug, under in vivo conditions, using a rat model. Different sets of co-axial ESNFs were 
produced to achieve fiber-by-fiber switching between specific time periods.156 The rat model 
illustrated a constant drug release of 116.6 μg/day with only a very small amount of drug 
leakage in the peripheral blood (<100 ng), rendering a long-term (>4 months) survival rate of 
85.7%.156 Similarly, G. Xia et al.151 developed a Gemcitabine (GEM)-based implantable 
system against pancreatic ductal adenocarcinoma in BALB/c athymic mice. The system 
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consisted of GEM dispersed in hyaluronic acid (HA) hydrosol (forming the sol solution) 
enwrapped with PLA-HA (electrospinning solution) to form core-shell (GEM@PLA-HA) 
ESNFs via sol-electrospinning. Although the antitumor effect of the developed system was not 
superior to that of GEM intravenous administration, due to the localized approach the mice 
implemented with the GEM@PLA-HA ESNFs presented a more efficient inhibition of residual 
tumor growth and a significantly reduced liver toxicity. Such a system could be implanted upon 
tumor removal for the prevention of tumor reoccurrence locally.151 Earlier this year, Hyun Mu 
et al.157 developed an injectable short PLA cytokine immobilized (Cyto-sPLA) system. The 
Cyto-PLA nanofibrous mats were produced via electrospinning. The produced ESNFS were 
then dispensed in ethanol, microtomed, and filtered to obtained Cyto-sPLA ESNFs with length 
ranging from 15-100 μm. Ethanol-based aqueous solutions consisting of polydopamine (pDA) 
conjugated IL-2 Fc immobilized Cyto-sPLA ESNFs were injected near the targeted tumor site 
in mice. The treated mice presented a significantly increased number and proportion of CD8+ 
T cells for up to 9 days, presenting retarded tumor progression with an up to 70% tumor 
regression.157 This is an innovative immunotherapeutic approach towards the reinvigoration of 
the body's non-functional CD8+ cells for suppressing tumor growth.157 The results of these 
studies suggest a facile approach for the design of nanoscale targeted drug administration, 
while simultaneously validating nanofibrous assemblies as potential replacements to traditional 
therapeutics. 
Table 5. Different drug release mechanisms.158
Release exponent (n) Drug Transport Mechanism Rate as a function of time
≤ 0.45 Fickian Diffusion t-0.5
0.45 < n < 0.89 Non-Fickian (Kinetic) Transport t(n-1)
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*drug release is constant and controlled by polymer relaxation
**drug release is polymer erosion-controlled
Characterizing the drug pharmacokinetics in ESNFs is difficult due to the complex 
morphologies of these polymer matrices and the structural variations they may undergo due to 
swelling. Various mathematical models have been proposed to describe drug release kinetics 
including first order models, the Higuchi model, the Hixson-Crowell model, and the 
Korsmeyer-Peppas model. Good success has been achieved in the Korsmeyer-Peppas 
framework, which models the release kinetics as a general power-law derived from a polymeric 
system, and can be modified to compensate for burst-release responses158: 
                                                  (1)
𝑀𝑡
𝑀∞ = 𝐾𝑘𝑝𝑡𝑛
Where  is the amount of drug released in time t,  is the amount of drug released after 𝑀𝑡 𝑀∞
time , n is the diffusional exponent or drug release exponent, and   is the Korsmeyer ∞ 𝐾𝑘𝑝
release constant. 
Release kinetics are evaluated using the logarithmic form of equation 1158 :   
              (2)log ( 𝑀𝑡𝑀∞) = log (𝐾𝑘𝑝) + 𝑛log (𝑡)
By plotting against log(t), a linear plot with a gradient of n and an intercept log (𝑀𝑡 𝑀∞) 
of  may be obtained. To determine whether the mechanism occurs by diffusion, log (𝐾𝑘𝑝)
leaching, or a combination of the two, the exponent variable n is used to describe drug release 
in cylindrical shaped matrices (and occasionally thin films)28. Table 5 provides the mechanism 
boundaries.
0.89 Case II Transport* Zero order release
> 0.89 Super Case II Transport** t(n-1)
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If the release mechanism does not conform to the application, the ESNF-drug matrix has 
been designed for (such as a reservoir-type therapeutic device exhibiting Case II transport as 
opposed to Fickian diffusion) then process parameters (such as applied voltage or polymer 
supply rate) may be adjusted to alter the fiber architecture. Various modified forms of equation 
1-1 have appeared in previous drug release studies, given in Table 6.
Table 6. Strategies for sustained drug release from ESNFs.
PCL = Polycaprolactone; PVA = Polyvinyl alcohol; PLLA = Poly(L-lactic acid)  PEG = 
Polyethylene glycol; PLGA = Poly(lactic-co-glycolic) acid; TFV = Tenofovir; AZT = 
azidothymidine; RAL = Raltegravir.  is the amount of drug released at time t,  is the 𝑀𝑡 𝑀∞
amount of drug released at time ,  is the burst release,  is the Korsmeyer release ∞ 𝑀𝑏 𝐾𝑘𝑝
constant, n is the diffusional exponent or drug release exponent, h is the height of the cylinder, 
Fiber System Agent Release 
(%)
Release Model Ref.
Name Loading 
(wt. %)
1 h 24 h 7 d 14 d
PCL:PVA Metoclopramide 
hydrochloride
1 5 55 65 68
𝑀𝑡 = [2𝜋ℎ𝐷𝜑𝐶𝑠ln (𝑟𝑜 𝑟𝑖)]𝑡 159 
PLLA:PVA Metoclopramide 
hydrochloride
1 2 12 22 25
𝑀𝑡 = [2𝜋ℎ𝐷𝜑𝐶𝑠ln (𝑟𝑜 𝑟𝑖)]𝑡 159
PCL:Gelatin Metronidazole 33.4 5 60 95 100
𝑀𝑡 = [2𝜋ℎ𝐷𝜑𝐶𝑠ln (𝑟𝑜 𝑟𝑖)]𝑡 160 
28%Zein:1%Ferulic 
Acid
Ketoprofen 10 5 100 - - 𝑀𝑡
𝑀∞
= 𝐾𝑘𝑝𝑡𝑛 161 
PCL:PLGA TFV, AZT, RAL 15 12 28 56 - 𝑀𝑡
𝑀∞
= 𝐾𝑘𝑝𝑡𝑛 162
PCL:PEG Salicylic acid 10 10 25 40 100 𝑀𝑡
𝑀∞
= 𝑀𝑏𝑀∞ +  𝐾𝑘𝑝𝑡𝑛 163 
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ro is the outside radius of the fiber, ri is the inside radius of the fiber, D is the diffusion 
coefficient,  is the partition coefficient for the drug from the core to the shell, Cs is the steady 𝜑
state concentration.
The number of interrelated parameters affecting the release kinetics makes it difficult 
to provide any meaningful comparisons between the isolated studies listed in Table 6. Note, 
however, the difference in release rates between the PCL:PVA and PLLA:PVA fibers, keeping 
all other variables constant. Over twice as much metoclopramide hydrochloride is released 
from the PCL:PVA fiber compared to the PLLA:PVA fiber after 14 days. The authors attribute 
this observation to a far higher porosity in the PCL shell, which allowed direct access to the 
drug by the surrounding fluid, resulting in a predominantly burst release mechanism. On the 
contrary, the PLLA shell exhibited a fickian diffusion mechanism. This is but one example of 
many, yet it reflects the importance of material selection in mediating tumor-specific release 
of cytotoxic treatment. The PLLA:PVA fiber is more relevant in the context of ESNF-DDSs; 
reservoir-type DDSs have been applied to the treatment of breast,164 colorectal, lung, head, 
neck,165 and many more cancers. PLLA:PVA would be particularly good in the treatment of 
deep-seated tumors due to both PLLA and PVA being biodegradable, meaning prolonged in 
vivo treatment can be obtained without the need to remove the polymer matrix by operation 
once the treatment period is complete. 
5.3. The Current and Future Status of Drug-Loaded Electrospun Nanofibers
In the absence of approved alternative treatment methods, traditional therapeutic practices 
have been the focus of some practical reform. Similar to the novel therapeutic platforms 
highlighted in this review, systemic chemotherapeutic drugs have, quite unsuccessfully, 
endeavored at improved delivery efficiencies by incorporating cancer-targeting moiety. A 
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median of only 0.7% of injected chemotherapeutic agents reach solid tumors upon systemic 
administration, according to a recent 10-year long literature survey.166 Some instances of 
improved systemic treatment have been reported using combinatorial chemotherapy and 
photodynamic therapy nanohybrids167 or synergistic nanoparticle / chemotherapeutic drug 
hybrids168; however, interest has shifted to local rather than systemic administration methods. 
Naturally, there is an ongoing effort to not only clinically approve various novel therapeutic 
agents, for example, those listed in Table 7, but also to optimize their delivery platform for 
routine clinical application, like those listed in Table 8. Optimized delivery platforms may 
mitigate the current problems with systemic administration; however, several problems remain 
before ESNF DDSs transition to clinical trials. The essential ones are 1) secondary removal 
surgery of non-biodegradable scaffolds; 2) the potential hazard of residual solvent from the 
manufacturing process; and 3) the biological challenge of foreign-body administration.165 Of 
note is the complexity surrounding the third point, which was briefly discussed in Section 1 
and Section 3. It is one of the major objectives in site-specific delivery to overcome the 
biological barriers that preclude efficacious unloading of cytotoxic treatment which, currently, 
is a non-trivial yet surmountable task. As the mechanisms involved in hindering drug delivery 
become better understood, functional ESNF DDSs outside the confines of convention may be 
formulated to address these limitations.169 For instance, active-targeting micelles have been 
encapsulated in core/shell NFs by coaxially electrospinning micelle-doped-poly(vinyl alcohol) 
/ cross-linked gelatin. Compared to the traditional administration of micelles for cancer 
therapy, the implantable doxorubicin-micelle-loaded NF reduced the frequency of 
administration while retaining high efficacy against solid tumors.170 More recently, an 
implantable hierarchical-structured fiber device developed via microfluidic-electrospinning 
was capable of co-delivering Doxorubicin (DOX)-loaded micelles encapsulated within ESNFs 
synergistically with the tyrosine kinase inhibitor, apatinib (AP), loaded into the ENSF's 
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matrix.171 This system aimed to inhibit P-glycoprotein (P-gp), an ATP-dependent efflux pump 
by preventing the over-expression of the protein aiming to overcome multiple drug resistance 
(MDR). The device was implanted to nude mice bearing multidrug-resistant human mammary 
adenocarcinoma (MCF-7/Adr) tumors. The sustained release of AP continuously inhibited the 
P-pg efflux pump, allowing for an increased intracellular uptake of DOX. The system presented 
low systemic toxicity and significantly decreased tumor volumes in comparison to the single 
drug ESNFs and the intravenously injected mice.171
These active targeting approaches enhance the specificity of encapsulated cargo to 
diseased tissues, minimizing deposition in non-target locations. However, the apparent 
therapeutic superiority of active-targeting approaches over non-targeting approaches is still a 
matter of some debate, with somewhat paradoxical results being reported in the literature.172 
Several studies have reported an improved efficacy and uptake of ligand-targeted therapeutics 
in neoplastic cells relative to their non-targeted analogs,170,173,174 while conversely there are 
studies that report no improvement in bioavailability of ligand-targeted therapeutics at tumor 
sites.175 This is perhaps a contributing factor as to why only one active-targeting nanomedicine, 
Ontak®, has been FDA-approved (as of 2016).62,176 It is more likely that economical and 
regulatory limitations heavily contribute to the lack of currently-available ESNF DDSs. From 
start to finish, an estimated 10-15 years and $1 billion worth of pre-clinical / clinical phase 
testing are required before therapeutics become available on the market.62 The limitations in 
pharmaceutical development are typically centered on four common trajectories: 1) reliability 
of the marketed product; 2) scalability of the manufacturing process; 3) chemical instability or 
denaturation of therapeutic compounds during manufacturing; and 4) long term stability of 
product after administration.177 As such, accurate characterization of the polymeric carrier-drug 
matrix is a necessary pre-requisite before predicting its behavior in a biological context. This 
is an important issue if ESNF DDSs are to progress beyond theoretical intrigue.62 There are 
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other significant steps involved in reaching clinical trial phases, but it is out with the scope of 
this review to highlight them in detail; the reader is referred to references62,141,177 for a more 
comprehensive account. 
Table 7. Examples of Nanoparticle-based therapeutics in clinical trial phases.
Therapeutic 
Agents
Target Cancer Clinical Trial 
Phases
Type Recruitment 
Status
Trial ID 
(ClinicalTrials.gov)
Carbon 
nanoparticle
Rectal Cancer Not applicable Lymphatic 
tracer
Not yet 
recruiting
NCT03550001
Carbon 
nanoparticle
Thyroid Cancer Not applicable Lymphatic 
tracer 
Completed NCT02724176
BIND-014, 
docetaxel 
nanoparticle
KRAS Mutation 
Positive or 
Squamous Cell 
Non-small Lung 
Cancer
Phase II Second-line 
treatment 
Completed NCT02283320
S-1, Albumin-
bound paclitaxel 
nanoparticle
Advanced 
Pancreatic 
Cancer
Phase II First-line 
treatment 
Active, Not 
recruiting
NCT02124317
Bevacizumab 
(biological), 
gemcitabine 
hydrochloride 
(drug), S-1 
(drug)
Breast Cancer Phase II First-line 
treatment
Completed NCT00662129
Paclitaxel 
albumin-
stabilized 
nanoparticle
Ovarian, 
Peritoneal
Cancers
Phase I First-line 
treatment 
Completed NCT00825201
Magnetic 
nanoparticle
Prostate Cancer Early Phase I Treatment Completed NCT02033447
CRLX101, 
enzalutamide 
Metastatic 
Castration 
Resistant 
Prostate Cancer 
Phase II First-line 
hormonal 
therapy, 
Treatment 
Recruiting NCT03531827
DOTAP:Chol-
fus1 
nanoparticle
Lung Cancer Phase I Treatment Recruiting NCT01455389
EktoTherix™
Tissue Repair 
Scaffold
Non-melanoma 
Skin Cancer,
Basal Cell 
Carcinoma,
Squamous Cell 
Carcinoma
Not applicable Treatment Completed NCT02409628
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Despite the many benefits that ESNF DDSs boast, a major liability to their adoption as 
primary point-of-care is the initial burst release of drugs upon intravenous administration.9 This 
attribute is observed in many diffusion-release ESNF delivery platforms, like some of those 
listed in Table 8, which diminishes or undermines the intended application. For example, 
recently Gemcitabine-loaded poly(L-lactate) / hydrosol ESNFs were fabricated by Xia et al151 
for the purpose of pancreatic recurrence prevention. In vitro and in vivo studies suggest the 
manufactured drug-polymer platform is well suited for abating residual cancerous cell 
proliferation after primary-care surgery. However, initial burst-release of up to 29.8% in the 
first day of loaded Gemcitabine was observed upon administration, with subsequent controlled 
release for up to 3 weeks after. This poses some inherent complications. Firstly, the ESNF 
platform may only be implanted once, which concerns the long-term objective of localized 
treatment, and secondly, this form of treatment cannot significantly increase the concentration 
of therapeutic agents in the blood. The results, while promising, must demonstrate a 
transferable efficacy in humans before progressing to a clinical trial phase. Foremost, the 
remarks of the authors reiterate a common caveat in the literature: secondary removal of the 
ESNF platform is required if it is not biodegradable. The biodegradability component is a 
subject of great interest for localized DDSs. It has been remarked that the continued 
advancement of biodegradable ESNF DDSs might facilitate a more rapid transition of the 
nanotherapeutic field from promising to commonplace,165 as, indeed, most currently approved 
nanoparticle-loaded platforms consist of simple analogs of well-described approved drugs.62 
From a purely scientific perspective, improvements in the biological understanding of diseased 
states and how they interact with administered ESNF DDSs, along with improvements in 
materials engineering, will serve to expand upon the already encouraging results reported in 
this review and advance nanotherapeutics into commonplace application. 
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Table 8. Some examples of promising ESNF DDS platforms.
Therapeutic 
Agent
Materials and Methods Drug Release 
Studies
In vivo studies In vitro studies Ref.
Ampicillin Different concentration of 
ampicillin were blended with 
core/shell poly(methyl 
methacrylate)/nylon6 NFs by 
coaxial electrospinning
Smooth 
core/shell fibers 
encapsulating 
variable 
concentrations of 
ampicillin were 
obtained, giving 
a sustained 
release of non-
Fickian diffusion 
(stage 1), and 
Fickian diffusion 
(stage 2 and 3) 
mechanisms 
over a 1 month 
period. 
N/A The antibacterial 
activity of the 
system was 
verified by means 
of optical density 
measurements 
against Gram-
positive L. 
innocua.
178
Acetaminophen Drug loaded Core/shell 
poly(vinyl pyrrolidone)/ethyl 
cellulose NFs were fabricated 
using a Teflon-coated 
concentric spinneret in a 
modified coaxial 
electrospinning set-up.
Amorphously 
distributed 
acetaminophen 
core-shell NFs 
with linear 
morphologies 
and clear core-
shell structures 
were obtained, 
exhibiting 
tunable dual 
drug controlled-
release profiles 
over a minimum 
of 24 hours.  
N/A N/A 179
Doxorubicin 
(DOX)
Core-shell structured 
NaGdF4
Yb/Er@NaGdF4:Yb@mSiO2 
-polyethylene glycol 
nanoparticles loaded with the 
antitumor drug, doxorubicin, 
were incorporated into 
poly(ε-caprolactone)  and 
gelatin loaded with 
antiphlogistic drug, 
indomethacin, to form NFs 
via electrospinning process. 
Burst release of 
therapeutic agent 
(60% in the first 
15 hours) and 
subsequent 
diffusional 
release (80% 
cumulative 
release after 64 
hours). 
Multifunctional 
spinning pieces 
were surgically 
implanted at 
the tumor sites 
of mice as part 
of orthotopic 
chemotherapy 
by controlled-
release of 
Doxorubicin 
from 
mesoporous 
SiO2. The 
inflammatory 
response was 
suppressed, 
helping wound 
healing in vivo.
N/A 180
Doxorubicin 
(DOX)
Graphene Sustained release 
of DOX 
following a 
N/A Cell viability 
results showed 
the higher 
181
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Oxide / TiO2 / DOX 
composites were loaded into 
chitosan/poly(lactic acid) 
(PLA) solutions to fabricate 
electrospun chitosan / PLA / 
GO / TiO2 / DOX NF 
scaffolds via electrospinning 
process.
small burst 
release was 
achieved from 
NF scaffolds 
with 30 and 
50μm 
thicknesses 
within two 
weeks 
incubation time. 
The faster DOX 
release rate from 
NFs was 
obtained in pH 
5.3 compared to 
pH 7.4. 
Korsmayer-
Peppas kinetic 
model was used 
to determine the 
DOX release 
mechanism. 
proliferation 
inhibition effect 
of NFs on target 
lung cancer cells 
in the presence of 
a magnetic field.
Mycophenolic 
acid (MPA) 
Coaxial fibers with poly(ε-
caprolactone) (PCL)/MPA 
core and PCL sheath NFs 
were produced using 
traditional and coaxial 
electrospinning techniques 
MPA-
encapsulated 
coaxial fibers 
exhibited 
sustained release 
of cytotoxic 
treatment over a 
100-hour period 
while MPA-
incorporated 
single fibers 
exhibited burst-
release 
mechanics.  
N/A In vitro 
glioblastoma 
multiforme 
(GBM) tumour 
cell culture 
results 
demonstrated 
strong cell 
suppression, with 
coaxial fibers 
inhibiting GBM 
cell growth 3-5x 
more than single 
fiber membranes  
182
Niflumic acid 
(NIF)
High throughput production 
of mats with PVP via nozzle-
free electrospinning process. 
The product was then mixed 
with microcrystalline 
cellulose for capsule 
formulation.
Amorphous NIF 
was formed. The 
dissolution rate 
of the capsule 
formulation 
showed a 14-fold 
increase within 
the first 15 
minutes.
N/A N/A 143
Temozolomide 
(TMZ)  
TMZ was initially loaded into 
chitosan nanoparticles and 
synthesized CS/TMZ 
nanoparticles were 
incorporated into the 
synthesized poly (ε-
caprolactone diol) based 
polyurethane (PCL-Diol-b-
PU) NFs using 
electrospinning techniques
Sustained TMZ 
release for 30 
days with the 
zero-order 
kinetic model 
was achieved 
from both 
CS/TMZ loaded 
PCL-Diol-b-PU 
and gold-coated 
NFs 
N/A Cell viability 
results indicated 
that the gold-
coated NFs can 
effectively inhibit 
the growth of U-
87 glioblastoma 
cells
183
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6. CONCLUSIONS AND OUTLOOK
Electrospinning has become a valuable means of producing functional ESNFs with unique 
morphological properties for biosensor and DDS applications. More research is being 
conducted into understanding the interactions that govern the overall effectiveness of these 
therapeutic platforms, and technological advancements in the field of nanoscale biomedicine 
is assisting the transition into localized point-of-care treatment methodologies. Biomarkers and 
biological analytes provide meaningful information in cancer diagnostics and treatment. 
However, their low concentration in complex biological media for early-stage cancers requires 
an ultrasensitive, highly specific, reproducible sensing device. The sensitivities of many ESNF-
based biosensors are now mature enough to detect cancerous analytes in bodily fluids, 
providing the necessary framework for non-invasive sampling. They may be applied routinely 
as well, outputting accurate results with minimal maintenance and handling expertise; this is 
in stark contrast to traditional methods of analysis, which are often time-consuming, require 
trained personnel, and can be very costly. It is without a doubt that ESNF-based biosensors and 
DDSs are recognized as very promising areas of research in the field of cancer therapeutics, 
but they currently represent a niche compared to the total pharmaceutical and medical device 
market.   
Many ESNF-based biosensors have been developed and reported in this literature review, 
utilizing a diverse inventory of polymers and approaches, incorporating or not nanoscale 
building blocks with pre- or post-treatment processes to produce biosensor platforms with 
improved analytical performance and functionality. It is challenging to identify which method 
of detection is the most appropriate, considering the many parameters involved in synthesizing 
an ESNF-based biosensor. Few biosensors rival the degree of molecular recognition – and the 
ultra-sensitivities that result – offered by enzymatic ECBSs, however, which is why most 
biosensors reported in literature rely on this method of transduction. To that end, spatial 
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architectures of NFs, electrode materials, immobilization techniques, and nanoscale building 
block dispersion strategies have been the object of much experimental effort, all of which can 
be incorporated within an ESNF framework. It is expected that by exploiting the versatility of 
electrospinning, ESNF-based biosensors and DDSs can be expanded to a broader range of 
cancers by immobilizing and maintaining a broader range of bioactive agents. Nevertheless, 
relatively few of these therapeutic platforms have been employed practically, and there are 
currently no commercially available devices. To validate them as primary point-of-care 
sampling and treatment devices, research towards multi-analyte / multi-drug systems is 
required. Simultaneous measurement of cancerous analytes will improve the biosensor’s 
diagnostic value, as many overexpressed biomarkers are indicative of a range of cancers. 
Additionally, sequestration of multiple therapeutic agents in a single ESNF matrix can be an 
effective means of inhibiting metastatic tumors, which is important in improving mortality rates 
for cancer patients. Some constraints, such as currently unobtainable economies of scale, 
complex synthetic routes, and legislative limitations have kept ESNF-based biosensors / DDSs 
in pre-clinical and clinical trial stages. Yet, the rate of their development promises that they 
will debut in routine clinical application in the foreseeable future. 
ABBREVIATION LIST
CBS = Calorimetric Biosensor 
CNT = Carbon Nanotube
DDS = Drug Delivery System 
ECBS = Electrochemical Biosensor 
ECM = Extracellular Matrix
ESNF = Electrospun Nanofiber
GQD = Graphene Quantum Dot
MBBS = Mass-Based Biosensor 
MPS = Mononuclear Phagocytes System 
MWCNT = Multiwall Carbon Nanotube
NF = Nanofiber
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OBS = Optical Biosensor 
QD = Quantum Dot
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This review describes the fabrication, properties, and applications of electrospun nanofibers 
as promising materials for the construction of nanoscale biosensors and therapeutic platforms 
for cancer diagnosis and treatment.
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 This review describes the fabrication, properties, and applications of electrospun nanofibers as promising 
materials for the construction of nanoscale biosensors and therapeutic platforms for cancer diagnosis and 
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